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Abstract
Background and aims. Epidemiological data on autoimmune hepatitis (AIH) are scarce. In this study, we determined the
clinical and epidemiological characteristics of AIH patients in the Netherlands (16.7 million inhabitants). Methods. Clinical
characteristics were collected from 1313 AIH patients (78% females) from 31 centers, including all eight academic centers in
the Netherlands. Additional data on ethnicity, family history and symptoms were obtained by the use of a questionnaire.
Results.The prevalence of AIH was 18.3 (95% confidential interval [CI]: 17.3–19.4) per 100,000 with an annual incidence of
1.1 (95% CI: 0.5–2) in adults. An incidence peak was found in middle-aged women. At diagnosis, 56% of patients had fibrosis
and 12% cirrhosis in liver biopsy. Overall, 1% of patients developed HCC and 3% of patients underwent liver transplantation.
Overlap with primary biliary cirrhosis and primary sclerosing cholangitis was found in 9% and 6%, respectively. The clinical
course did not differ between Caucasian and non-Caucasian patients. Other autoimmune diseases were found in 26% of
patients. Half of the patients reported persistent AIH-related symptoms despite treatment with a median treatment period of
8 years (range 1–44 years). Familial occurrence was reported in three cases. Conclusion. This is the largest epidemiological
study of AIH in a geographically defined region and demonstrates that the prevalence of AIH in the Netherlands is uncommon.
Although familial occurrence of AIH is extremely rare, our twin data may point towards a genetic predisposition. The high
percentage of patients with cirrhosis or fibrosis at diagnosis urges the need of more awareness for AIH.
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Autoimmune hepatitis (AIH) is a chronic inflamma-
tory liver disorder of unknown etiology, which when
left untreated can lead to hepatic failure and premature
death [1]. Women are affected more frequently than
men, and the disease can develop in all age groups.The
clinical spectrum is wide, ranging from absent or mild
symptoms to fulminant hepatic failure and may vary
among ethnic groups [2]. AIH has features that resem-
ble primary sclerosing cholangitis (PSC) and primary
biliary cirrhosis (PBC) andoverlapwith thesedisorders
are reported in10–20%and2–8%ofcases, respectively
[3,4]. Associated concomitant autoimmune diseases
in AIH have been reported in up to 40% of patients
and may mask the underlying liver disease [5].
There is no gold standard for the diagnosis of AIH,
and diagnosis is based on the combination of clinical
and laboratory findings and histological abnormalities
after exclusion of viral and other causes of hepatitis [6].
Diagnostic scoring systems have been developed that
help to make the diagnosis in the majority of patients
and are particularly useful for defining homogenous
patient groups in the context of studies [7].A simplified
scoring system with four variables was recently devel-
oped that enhances its applicability indaily practice [8].
There are few studies that have explored the
prevalence of AIH. Older studies were often per-
formed before the introduction of the diagnostic
scoring system and have been biased to a certain
extent by the fact that they do not rely on current
standard criteria for patients’ inclusion. Moreover,
early studies did not exclude patients with chronic
hepatitis C. Based on the available data, incidence of
AIH is considered to be low, ranging from 0.08 in
Japan [9] to 3 per 100,000 in the United Kingdom
[10]. In the current study, we assessed the incidence
and prevalence of AIH patients in the Netherlands
16.7 million inhabitants. In addition, we assessed the
clinical spectrum and validity of diagnostic criteria in
a large patient cohort of 1313 patients.
Material and methods
Patient population
Data for this retrospective study were retrieved from
computerized or written medical records in 31 centers
in the Netherlands, including 8 academic medical
centers and 23 general district hospitals (Figure 1).
Patients with AIH were identified based on informa-
tion provided by co-investigators in the participating
hospitals, by review of local AIH databases and
by searching the database for international disease
classification codes. The search was done in different
local diagnostic registers in gastroenterology and
internal medicine departments, but not in pediatrics.
Adult patients who were diagnosed during infancy
were likewise included. The medical records of AIH
patients were traced back as long as possible. Patients
included were diagnosed between 1967 and 2011.
The institutional review board of the VUUniversity
medical centre and the review boards of all participat-
ing centers approved the protocol. All participating
patients gave written informed consent.
Diagnosis and application of diagnostic scoring systems
We included patients who had been diagnosed with
AIH based on the combination of clinical, biochem-
ical and histopathological criteria. In all patients,
alcohol-induced and drug-related hepatitis had
been excluded by clinical history. Viral hepatitis
had been excluded by serological tests (hepatitis B
and C) in all cases. Diagnostic scores were deter-
mined according to both the International AIH
Group (IAIHG) revised original criteria [7] and the
simplified criteria [8]. In approximately half of the
patients, not all characteristics were available to cal-
culate the revised original criteria.
Incidence and prevalence
To accurately determine the incidence and preva-
lence, the Amsterdam geographic region was studied
Figure 1. Figure-map of The Netherlands with locations of the
hospitals included in this study.

























































as catchment area. In this region, there are two
academic hospitals and four regional hospitals.
Many of the patients in the academic centers were
referred from general district hospitals outside
Amsterdam (50%). Patients who were referred
from outside the region were excluded from this
analysis.
Patient characteristics
As all the datawere collected from routine practice and
diagnostic work-up, the available data could vary
between participating hospitals. The following patient
data were collected: gender, date of birth, date of
diagnosis, characteristics of AIH (original and simpli-
fied criteria [7,8]) at diagnosis andduration and type of
therapy. In the eight academic centers, it was docu-
mented if a liver transplantation was performed and
when a patient developed a hepatocellular carcinoma
(HCC). Laboratory data was including alanine-ami-
notransferase (ALT), immunoglobulin gamma G
(IgG), smooth mussel antibodies (SMA) and antinu-
clear antibodies (ANA) were collected.
Details on portal, interface, overall inflammatory
activity and on fibrosis/cirrhosis were retrieved from
pathology reports when liver biopsy at diagnosis had
been performed.
With regard to concomitant autoimmune diseases,
the diagnosis of inflammatory bowel disease (IBD)
was based on clinical, endoscopic and histopatholog-
ical features, diabetes mellitus on fasting blood
glucose levels and thyroid disease by screening for
TSH, T4 and when applicable thyroid antibodies.
Diagnosis of overlap syndrome was made according
to the diagnostic criteria of the involved diseases [3].
For PBC, these criteria composed of antimitochon-
drial antibody (AMA) titer higher than 1:80 and com-
patible histology. For PSC, these criteria generally
were also based on histology and typical findings in
radiological investigations (MRCP/ERCP). Human
leukocyte antigen (HLA) typing was unavailable for
all patients. Type of maintenance therapy was docu-
mented at the time the registers were searched.
Patients were asked to fill out a questionnaire
assessing symptoms, family history and ethnicity. In
monozygotic and dizygotic twins disease concordance
was studied.
Statistical analysis
Summary statistics for continuous variables were
expressed as median with range (minimum–maxi-
mum). Summary statistics for categorical variables
were expressed as numbers (percentages). Quantita-
tive variables were described as means with their
standard deviations or as medians with their range
if not normally distributed. Categorical variables
were summarized with frequencies and percentages.
Depending on the distribution, parametric and non-
parametric tests, including t-test, Wilcoxon signed
rank test and Sign exact test, were used to test for
differences within and between groups. Cox regres-
sion univariate and multivariate analyses were used to
test the relationship between patient characteristics
and survival. The trend in incidence was measured by
the Cochran-Armitage Test for Trend. Two-sided
p-Values less than 0.05 were considered statistically
significant. Statistical analyses were performed using
Statistical Package for Social Sciences (SPSS).
Results
Experimental design and cohort characteristics
This retrospective analysis characterized the epidemi-
ological characteristics of AIH in the Netherlands.
A total of 1313 AIH patients were identified; among
these patients, 12% had been diagnosed under the age
of 18 (Table I). Median follow-up time of this cohort
was 10 years (range: 0–44 years). There was a strong
female preponderance; 1020 (78%) were females.
The median age at diagnosis in females was 48 years
(range: 5–87 years) and in men 43 years (range: 6–
87 years; p > 0.05). An incidence peak in middle-aged
women was found, with a smaller peak in adolescents
(Figure 2). In men, no specific age-related incidence
peak was observed.
The population of the Netherlands consists of 16.7
million inhabitants, of which ~ 2 million (12%) are of
non-Western descent (source: Statistics Netherlands;
http://www/cbs.nl). This was reflected in the patient
cohort. Among the 564 patients who reported their
ethnic background in the questionnaire, 501 (89%)
were Caucasians, whereas 63 (11%) of patients
reported another background, mostly of African
(34%), Asian (16%), South American (16%) and
European (11%) descent. It has been reported that
disease manifestations of AIH may vary among ethnic
groups [11]. However, in this study cohort, no
significant differences could be observed in the
frequency of cirrhosis and fibrosis, ALT levels, anti-
bodies, IAIHG disease scores according to the orig-
inal and simplified criteria at presentation between
Caucasian and non-Caucasian patients (p > 0.05 for
all parameters; data not shown).
Incidence and prevalence
Incidence and prevalence figures were determined in
the Amsterdam area, covering a population of

























































799,000 individuals (data: Statistics Netherlands) and
extrapolated to the rest of the country. A total of
146 AIH patients were identified in the catchment
area. According to these numbers the point preva-
lence in the Netherlands is 18.3 (95% confidential
interval [CI]: 17.3–19.4) per 100,000.
The incidence was calculated over a time span of
10 years. Between 2000 and 2010, an average of
77 (range: 47–107) new AIH patients were diagnosed
in the participating hospitals. An average of nine
patients per year was diagnosed in the catchment
area (Figure 3), resulting in an overall incidence in
the Netherlands of 1.1 per 100,000 per year (95% CI:
0.5–2). Remarkably, there was a significant rise in
incidence over the past 10 years in both the catchment
area (p < 0.01) and in the overall cohort (p < 0.01).
The incidence and prevalence of AIH was further
confirmed using another approach. Based on the
hospital size (inferred from the number of beds and
referrals), it is estimated that the 23 large hospitals
included in this study (out of a total of 99 hospitals in
the Netherlands) serve approximately 45% of the
population. Extrapolating the number of patients
identified in the participating hospitals to the total
population would result in a prevalence of 18.7 per
100,000, very similar to the prevalence data tabulated
from the catchment area.
Scores according to the revised original [7] and simplified
[8] AIH diagnostic criteria
This analysis was performed in subgroups of patients
with sufficient data to calculate the scores. Results of
HLA typing were not available for our patients. The
revised original criteria were assessed in 618 patients.
The median post-treatment score at presentation in
these patients was 19 points (range: 8–26 points).
A total of 596 (97%) of patients fulfilled the diagnostic
criteria for AIH; among these 442 (72%) patients
could be classified as definite AIH and 154 (25%)
as probable AIH. Among the 22 patients who did not
fulfill the revised original criteria, 17 (77%) had
evidence for an overlap syndrome, in particular
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Figure 2. Age at diagnosis of AIH in males and females.





(n = 193) (n)
Gender (female/male); n 1020/293 865/255 142/51 1313
Median age males; y (range) 43 (6–87) 43 (8–87) 40 (6–82) 293
Median age females; y (range) 48 (5–87) 46 (8–87) 44 (5–84) 1020
Median ALT; IU/l (range) 299 (10–6667) 368 (20–6672) 255 (10–5523) 1295
Median IgG; g/l (range) 22 (6–42) 25 (8–42) 20 (6–28) 1206
Median ALP; IU/l (range) 149 (16–7107) 119 (16–6204) 263 (111–7107) 1270
SMA pos; n (%) 564 (52%) 530 (58%) 80 (46%) 1089 (912/175)
ANA pos; n (%) 610 (53%) 476 (49%) 88 (49%) 1152 (972/180)
Cirrhosis/fibrosis (biopsy); n (%) 128/580 (12%/56%) 108/480 (12%/55%) 20/100 (12%/58%) 1041 (869/172)
Decompensated liver cirrhosis; n (%) 66 (9%) 59 (9%) 7 (6%) 730 (657/115)
HCC; n (%) 8 (1%) 7 (1%) 1 (1%) 730 (657/115)
Liver transplantation; n (%) 25 (3%) 19 (3%) 6 (5%) 772 (657/115)
Abbreviations: AIH = Autoimmune hepatitis; ALP = Alkaline phosphatase; ALT = Alanine transaminase; ANA = Antinuclear antibodies;
HCC = Hepatocellular carcinoma; IgG = Immunoglobulin G; PBC = Primary biliary cirrhosis; PSC = Primary sclerosing cholangitis
SMA = Smooth muscle antibodies.

























































not fulfill the diagnostic criteria for AIH can be
attributed to the fact that in case of AMA positivity
4 points are subtracted from the total score.
A total of 749 patients could be classified according
to the simplified criteria. The median score was 6.4
points (range: 2–8 points). According to this classifi-
cation, 171 (23%) had probable AIH and 387 patients
(52%) definite AIH, whereas 191 (25%) patients did
not fulfill the criteria for the diagnosis AIH (Table II).
Among the patients who did not fulfill the diagnosis
AIH according to the simplified criteria, 56 (29%)
had an overlap with either PBC (n = 32) or PSC
(n = 24).
In 618 patients, parameters for both the revised
original and the simplified criteria were available.
Four hundred and seventy of these patients (76%)
fulfilled the criteria for either definite or probable
AIH according to both scoring systems. A total of
110 patients (18%) with AIH according to the revised
original criteria (79 with probable and 31 with definite
AIH) did not fulfill the criteria for AIH according to
the simplified criteria. Vice versa, six patients (five
probable and one definite; 1%) fulfilled the diagnosis
for definite or probable AIH according to the simpli-
fied criteria, but not according to the revised original
criteria (Table III).
Laboratory values, antibodies and liver biopsy
Laboratory values. In this cohort, ALT levels were
above upper limit of normal (ULN) at diagnosis in
93% of patients, with a median ALT level of 299 IU/l
(range: 10–6672) (Table I). In 58% of patients, ALP
was not concomitantly elevated with ALP/ALT ratios
<1.5 in 79% of all AIH patients.
Total serum IgG was above ULN in 83% of the
patients with 60% of patients displaying levels >1 g/l
above ULN. The median IgG level was 22 g/l (range:
6–42).
In 36% of patients (n = 473), all three conditions
(ALT>ULN, ALP<ULN and IgG>ULN) were met at
diagnosis.
Antibodies. ANA was measured in 1152 patients
(88%) and SMA in 1089 (83%) at the time of diag-
nosis. Data on both antibodies could be retrieved
from 1012 patients (77%). In 53% of patients,
ANA was positive and in 52% SMA positivity was
found (Table I). Both antibodies were positive in
380 (38%) of patients, whereas 861 patients (85%)
tested positive for at least one of these antibodies. -
liver kidney microsomal-1 antibodies (LKM-1) were
measured in 78 patients. Four patients tested positive,
three of them being under the age of 18 years.
Liver biopsy. In 1041 (79%) patients, diagnosis was
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Figure 3. Incidence rates of AIH between 2000 and 2010.








Definite AIH 442 (72%) 41 (9%)
n = 618 Probably AIH 154 (25%) 34 (22%)
No AIH 22 (3%) 17 (77%)
Simplified
criteria**
Definite AIH 387 (52%) 48 (12%)
n = 749 Probable AIH 171 (23%) 15 (9%)
No AIH 191 (25%) 56 (29%)
*Revised diagnostic scoring system of the international Autoim-
mune Hepatitis group (IAIHG) [7].
**Simplified criteria of the IAIHG [8].

























































necrosis (interface hepatitis) was reported in 903
patients (87%), plasma cells in 791 patients (75%)
and rosettes were described in 163 patients (16%). At
diagnosis, 580 (56%) patients had fibrosis and
128 (12%) patients had histological signs of cirrhosis
(Table I). Rosettes and interface hepatitis were sig-
nificantly more present in a biopsy with concomitant
fibrosis or cirrhosis versus a biopsy without fibrosis or
cirrhosis (p < 0.01 and p = 0.01, respectively).
In an effort to link the presence of fibrosis or
cirrhosis to biochemical parameters, we observed
that patients with a normal IgG had significantly
less fibrosis and cirrhosis than patients with elevated
IgG levels at the time of diagnosis (p < 0.05). No such
association was found with ALT levels.
Concurrent autoimmune disease
Concomitant autoimmune diseases were observed in
335 patients (26%). These included 121 (9%)
patients with thyroid disease, 63 (5%) with IBD, 52
(4%) with arthritis and 27 (2%) with type I diabetes.
Other reported autoimmune or immune-mediated
diseases included celiac disease, autoimmune hemo-
lytic anemia, sarcoidosis and multiple sclerosis. In this
study, 39 (3%) patients were diagnosed with more
than one concomitant autoimmune disease. Signifi-
cantly, more women than men (27% vs. 21%; p =
0.02) had a concomitant other autoimmune disease.
Overlap syndrome
Concurrent features of PBC or PSC are frequently
observed in AIH. In our AIH cohort, 113 of 1313
patients (9%) were diagnosed with PBC and
80 patients (6%) exhibited an overlap syndrome
with PSC. Patient characteristics are summarized in
Table I.
Biochemical and serological features of AIH were
generally less pronounced in cases with overlap
syndrome. Thus, mean ALT levels were lower in
the group of patients with overlap syndrome
(255 IU/l [range: 10–5525] vs. 368 IU/l [range:
20–6672]; p < 0.01). Similarly, the percentage of
patients with ALT levels above ULN was lower in
this patient category (87% vs 93%). In the overlap
group, 72% had IgG levels above ULN with a mean
IgG level of 20 g/l (range: 6–28) versus 83% of
patients without overlap with a mean level of 25 g/l
(range: 8–42) (p < 0.01).
SMA was positive in 46% of overlap patients versus
58% in the remaining AIH patients (p = 0.04),
whereas the frequency of ANA positivity did not differ
between the two groups (~50%).
Self-reported disease onset and symptoms
During the period, 38 (3%) patients were diseased
when the questionnaire was sent. A total of 564 (44%)
of the 1275 patients, including 472 females (84%) and
92 males (16%), returned the questionnaire. The self-
reported information was collected a mean of 7 years
after diagnosis (range: 1–25 years). A symptomatic
disease onset was reported in 288 (51%) of patients
and included mainly jaundice (45%) and fatigue
(51%) (Table IV). Forty-seven percent of patients
Table III. Comparison of the two scoring systems for the diagnosis AIH.
Patients with simplified criteria**
No AIH Probable AIH Definite AIH Total
Patients with revised original criteria* No AIH 16 5 1 22 (3%)
Probable AIH 79 33 42 154 (25%)
Definite AIH 31 68 343 442 (72%)
Total 126 (20%) 106 (17%) 386 (63%) 618
*Revised diagnostic scoring system of the international Autoimmune Hepatitis group (IAIHG) [7].
**Simplified criteria of the IAIHG [8].
Table IV. Self-reported patient characteristics.
Features n = 564
Percentage
(%)




Symptomatic onset disease 288 51
Fatigue 130 45
Joint pain 147 51
Abdominal pain 26 9
Symptoms despite treatment: 267 47
Fatigue 165 62
Fatigue and abdominal pain 30 11
Fatigue and joint pain 22 8
Other 50 19
First-degree family member
with other autoimmune disease
236 42
Direct family member with AIH 2 0.3
Disease concordance in
Monozygotic twins (n = 1) 1 100
Dizygotic twins (n = 5) 0 0

























































reported persistent AIH-related symptoms despite the
instituted immunosuppressive treatment. The most
common symptoms were fatigue, joint pain and
abdominal pain (Table IV).
Familial occurrence
Data on familial occurrence and ethnicity were
reported by 564 AIH patients. Among these,
236 patients (42%) reported a first-degree family
member with another autoimmune disease; thyroid
disease (20%), type I diabetes (14%) and arthritis
(9%) being the most common. Two patients (0.3%)
had a relative with AIH. One patient had a mother
diagnosed with AIH and the other a cousin. In addi-
tion, there was one monozygotic twinpair in this
cohort, and both individuals had AIH. Among the
five dizygotic twins, no disease concordance was
found in any of the twin pairs (Table IV).
Medication
In 1284 patients, maintenance treatment was docu-
mented. A total of 627 patients (49%) used combi-
nation therapy of prednisone and azathioprine,
whereas 437 (34%) used monotherapy (either pred-
nisone or azathioprine). Around one-fifth of the
patients (17%) were not using maintenance therapy.
In these 220 patients without maintenance therapy,
38 patients (17%) did not satisfy the simplified or the
revised original diagnostic criteria of the IAIHG.
Patients using combination therapy had a higher
mean diagnostic score at diagnosis (18.1 points
according to the original criteria) when compared
to patients on monotherapy (17.4 points) and patients
without medication (14.2 points) (p < 0.01).
Clinical course
In the eight academic medical centers in the Nether-
lands (including all liver transplantation centers), the
clinical course of 730 patients (76% female) was
documented. The median follow-up time was 8 years
(range 0–44 years). In these patients, 120 (16%)
developed portal hypertension, after a median of
17 months following diagnosis (range: 0 months–
38 years). Sixty-six patients (9%) developed decom-
pensated liver cirrhosis after a median of 16 months
(range: 0 months–38 years). In this cohort, eight (1%)
patients were diagnosed with HCC, after a median of
6 years (range: 9 months–29 years) following diagno-
sis. Of the patients who developed a HCC, one patient
had an overlap with PBC, none with PSC. Six of these
patients had pre-existent cirrhosis.
Twenty-five (3%) patients underwent liver trans-
plantation after a median of 5 years (range: 8 months–
30years) following diagnosis. Five of these patients
had an overlap with PSC, one with PBC. In addition,
14 patients (2%) were screened for liver transplanta-
tion and are still on the waiting list.
Discussion
Epidemiological studies in AIH are scarce and the
actual prevalence is currently unknown. Previous
studies were hampered by the lack of uniform diag-
nostic criteria and were executed in either single
centers or tertiary referral hospitals or consisted of
mixed ethnic populations. In this large multi-centre
survey, we aimed to overcome some of these limita-
tions. In addition, we aimed to describe the clinical
characteristics of AIH in a well-defined large cohort of
patients. Hereto, patient records from not only all
eight academic hospitals in the Netherlands were
studied, as well as those from 23 regional non-
academic institutions population and comprises the
largest epidemiological AIH study so far. Also, the
catchment area for calculating incidence and
prevalence included a combination of academic and
non-academic hospitals and therefore presumably
embodies a representative reflection of the overall
AIH patient population. A mean annual incidence
of 1.1 per 100.000 per year and a point prevalence in
the Netherlands of 18.3 per 100.000 as calculated
from the catchment area was found. It should be
noted that the incidence data presented here might
slightly underestimate true incidence figures since
pediatric patients, who account for approximately
10% of patients, were not included in this survey.
In addition, occasional patients may have beenmissed
due to the fact that soluble liver antigen and LKM-1
antibodies are not routinely measured.
Although there is some variation, presumably due
in part to the considerations mentioned above, the
findings presented in this study are comparable to
studies from other European countries, including
Denmark, Norway, Sweden, the UK and Spain. Inci-
dence rates in these populations vary between 0.8 and
3 and prevalence data between 12 and 17 [10,12–15].
A study from New Zealand reported an annual inci-
dence of 2.0 cases of AIH per 100,000 and a some-
what higher prevalence of 24.5 cases per 100,000
[16]. A study in well-defined Alaskan native AIH
patients reported a significantly higher prevalence of
definite AIH of 35.9 cases per 100,000, with a par-
ticularly high prevalence in Southeast Indians. Unfor-
tunately, no incidence data were presented in this
study, and it should be noted that this study involved a
limited number of 56 patients in a catchment area of

























































100,312 individuals [17]. Finally in Japan, AIH
appears to be considerably less frequent than in West-
ern countries with an incidence estimated between
0.08 and 0.15 [18].
Of interest, a significant rise in incidence was seen
in our cohort during the last decade and may indicate
a true rise in incidence or, alternatively, increased
awareness and diagnostic accuracy. These findings
are in line with a previous observation from a single
center study in Spain [14].
As expected, women were more affected than men
with a sex ratio of 3.5:1 comparable to earlier studies
[11]. The age of first disease manifestation varies
greatly from early life until old age. In our cohort,
the bimodal incidence pattern was only confirmed in
women with a peak around the menopause [11].
Whether the incidence peak around menopause
relates to hormonal changes as suggested in other
autoimmune diseases warrants further research [19].
In our study population, 97% of patients satisfied
the criteria for probable or definite AIH. The small
group of patients who did not meet the criteria
included a high number of PBC overlap patients.
Although the original criteria have a high sensitivity,
the application of this scoring system is cumbersome
in daily clinical practice and therefore a simplified
scoring system was developed. Three retrospective
studies indicated that this simplified scoring system
had a somewhat lower yet acceptable sensitivity when
compared to the original revised criteria [20–22]. In
this retrospective cohort, however, we observed that
only 75% of patients with the clinical diagnosis AIH
met the criteria for probable or definite AIH using this
scoring system and in addition that almost one-fifth of
patients who could be classified as definite AIH
according to the revised original criteria did not fulfill
the diagnosis AIH according to the simplified criteria.
These findings indicate that at least in this large
retrospective cohort the original revised criteria are
superior to the simplified criteria. It should be noted
that these findings are limited by the fact that com-
parison of these scoring systems was not the purpose
of this study and that a significant number of patients
could not be scored due to lack of data.
In all but its mildest form fibrosis is often present at
diagnosis and with advanced disease bridging fibrosis
and cirrhosis are often seen in AIH [11]. In our study
cohort, more than half of the patients had fibrosis at
diagnosis and in addition already 12% had cirrhosis.
Similar or even higher cirrhosis rates have been
observed in other studies, which indicate that disease
has remained unrecognized for a significant period of
time prior to diagnosis [7,15]. This study confirms
earlier observations that the extent of histological dam-
age is not related to the presence of symptoms [23] and
thus urges the need for more awareness of the possi-
bility of this disease even in asymptomatic patients.
Concurrent immune disorders are surprisingly
common in AIH. One prospective study found that
concurrent autoimmune disease was present in 28%
of 122 patients [24]. The associated diseases may
antedate the appearance of AIH or occur after the
diagnosis has been established. The present study in a
very large cohort of patients confirms these findings
with thyroid disease being the most commonly asso-
ciated disease. Similarly, the co-existence of PBC or
PSC in this large cohort of patients is at the same
order of magnitude as reported earlier in smaller
cohorts (reviewed by Rust and Beuers that et al. [25]).
There are virtually no reliable data on familial
occurrence in AIH. Yet the occurrence of AIH in
members of the same family is an infrequent obser-
vation. One study explored familial occurrence in a
cohort of 219 patients, and in this cohort, three cases
were identified where both mother and daughter were
affected [26]. There is an additional case report
describing the occurrence of AIH in two sisters
[27]. In the present study, we collected data from
564 patients by the use of a questionnaire. Co-
occurrence of disease was identified in one mother-
daughter pair and in addition in one third-degree
relationship. Interestingly, the one monozygotic
twinpair was concordant for disease, whereas no
concordance was found in any of the five dizygotic
twin pairs. Although these data are limited, all point,
in addition to the established HLA association,
towards a complex genetic predisposition, possibly
with low penetrance [28]. This notion is further
supported by the high frequency of other autoimmune
disease, both within patients as well as in relatives of
patients, as noticed in our patient cohort as well as in
another study [29].
The development of HCC was previously regarded
as a rare complication of AIH. Three retrospective
studies described the development of HCC in 1–4%
of AIH cases [30–32]. In a prospectively followed
cohort, the rate HCC development was substantially
higher with 6.2% of all patients. This number was as
high as 9.3% in patients who had cirrhosis at presen-
tation [33]. In the present study, these numbers are of
the samemagnitude as the earlier retrospective studies.
AIH represents the indication for liver transplan-
tation in 4–6% of adults in both the US and Europe
[34–37]. In our cohort, 3% of AIH patients under-
went liver transplantation, whereas 2% were awaiting
transplantation. This percentage is probably overes-
timated, while the data on transplantation were only
collected from the academic centers and patients in
need for transplantation are transferred to these
centers.

























































In conclusion, this study represents the largest
nationwide study on the epidemiology of AIH so
far. The findings presented in this study confirm
that AIH is a relatively uncommon disease. The initial
presentation of AIH varies widely, and diagnosis can
be supported by the revised original criteria and, to a
lesser extent, by the simplified criteria. During diag-
nosis, 12% of the patients already have cirrhosis and
more than half of the patients fibrosis, which indicates
a delay in diagnosis. No significant differences were
observed in biochemistry, serologically and histology
between Caucasian and non-Caucasian patients.
Although familial occurrence is uncommon, the avail-
able data point towards the role of genetic factors in
disease predisposition. Overall, 1% of AIH patients
develop HCC and in 3% of patients, liver a trans-
plantation was performed. Prospective studies are
warranted to substantiate the value of laboratory
features, liver biopsy and to optimize the diagnostic
criteria at diagnosis.
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